Evidence map›Paper›PMID 27768710›Full record

ArticlePloS one2016

Loss to Follow-Up from HIV Screening to ART Initiation in Rural China.

Diane Gu, Yurong Mao, Zhenzhu Tang, Julio Montaner, Zhiyong Shen, Qiuying Zhu, Roger Detels, Xia Jin, Ran Xiong, Juan Xu and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. The Benefits of Immediate ART.Journal of the International Association of Providers of AIDS Care
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Diane GuThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Yurong MaoThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Zhenzhu TangGuangxi Center of Disease Control and Prevention, Nanning, Guangxi, China.
Julio MontanerBC Center for Excellence in HIV/AIDS, University of British Columbia, Vancouver, BC, Canada.
Zhiyong ShenGuangxi Center of Disease Control and Prevention, Nanning, Guangxi, China.
Qiuying ZhuGuangxi Center of Disease Control and Prevention, Nanning, Guangxi, China.
Roger DetelsDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, United States of America.
Xia JinThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Ran XiongThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Juan XuThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Walter LingIntegrated Substance Abuse Programs, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America.
Lynda ErinoffNational Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Robert LindbladThe EMMES Corporation, Rockville, MD, United States of America.
David LiuNational Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Paul Van VeldhuisenThe EMMES Corporation, Rockville, MD, United States of America.
Albert HassonIntegrated Substance Abuse Programs, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America.
Zunyou WuThe National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Guangxi Center for Disease Prevention and Control · CNEmmes (United States) · USNational Institute on Drug Abuse · USOASIS Clinic · USUCLA Health · USUniversity of British Columbia · CA

Funding

The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
NIDA NIH HHS U10 DA013045
6 · The paper itself

Abstract

backgroundPatients who are newly screened HIV positive by EIA are lost to follow-up due to complicated HIV testing procedures. Because this is the first step in care, it affects the entire continuum of care. This is a particular concern in rural China. OBJECTIVE(S): To assess the routine HIV testing completeness and treatment initiation rates at 18 county-level general hospitals in rural Guangxi.

methodsWe reviewed original hospital HIV screening records. Investigators also engaged with hospital leaders and key personnel involved in HIV prevention activities to characterize in detail the routine care practices in place at each county.

results699 newly screened HIV-positive patients between January 1 and June 30, 2013 across the 18 hospitals were included in the study. The proportion of confirmatory testing across the 18 hospitals ranged from 14% to 87% (mean of 43%), and the proportion of newly diagnosed individuals successfully initiated antiretroviral treatment across the hospitals ranged from 3% to 67% (mean of 23%). The average interval within hospitals for individuals to receive the Western Blot (WB) and CD4 test results from HIV positive screening (i.e. achieving testing completion) ranged from 14-116 days (mean of 41.7 days) across the hospitals. The shortest interval from receiving a positive EIA screening test result to receiving WB and CD4 testing and counseling was 0 day and the longest was 260 days.

conclusionThe proportion of patients newly screened HIV positive that completed the necessary testing procedures for HIV confirmation and received ART was very low. Interventions are urgently needed to remove barriers so that HIV patients can have timely access to HIV/AIDS treatment and care in rural China.

Indexed as

AIDS SerodiagnosisRural PopulationAnti-HIV AgentsChinaCross-Sectional StudiesFollow-Up StudiesHIV InfectionsHumansAnti-HIV Agents

Identifiers

PMID27768710
PMCPMC5074455
OpenAlexW2536489628

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.